Compare PGIM India Healthcare Fund vs UTI Healthcare Fund
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹1000 | ₹500 |
Expense Ratio | 2.37 | 2.27 |
NAV | ₹9.73 | ₹275.66 |
Fund Started | 19 Nov 2024 | 01 Aug 2005 |
Fund Size | ₹99.70 Cr | ₹1101.63 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 90 days. | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹1000
₹500
Expense Ratio
2.37
2.27
NAV
₹9.73
₹275.66
Fund Started
19 Nov 2024
01 Aug 2005
Fund Size
₹99.70 Cr
₹1101.63 Cr
Exit Load
Exit load of 0.50%, if redeemed within 90 days.
Exit load of 1% if redeemed within 30 days.
1 Year | -1.21% | -0.39% |
3 Year | - | 23.21% |
5 Year | - | 14.00% |
1 Year
-1.21%
-0.39%
3 Year
-
23.21%
5 Year
-
14.00%
Equity | 98.07% | 99.40% |
Cash | -0.20% | 0.59% |
Equity
98.07%
99.40%
Cash
-0.20%
0.59%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 11.72% |
Divi's Laboratories Ltd. | 9.97% |
Max Healthcare Institute Ltd. | 7.21% |
Aster DM Healthcare Ltd. | 6.23% |
Dr. Reddy's Laboratories Ltd. | 6.01% |
JB Chemicals & Pharmaceuticals Ltd. | 5.11% |
Mankind Pharma Ltd. | 4.65% |
Rubicon Research Ltd. | 4.29% |
Ajanta Pharma Ltd. | 3.92% |
Abbott India Ltd. | 3.61% |
Sun Pharmaceutical Industries Ltd. | 9.37% |
Ajanta Pharma Ltd. | 7.16% |
Lupin Ltd. | 5.65% |
Glenmark Pharmaceuticals Ltd. | 4.06% |
Gland Pharma Ltd. | 3.60% |
Procter & Gamble Health Ltd. | 3.46% |
Dr. Reddy's Laboratories Ltd. | 3.46% |
Cipla Ltd. | 3.43% |
Alkem Laboratories Ltd. | 3.40% |
Apollo Hospitals Enterprise Ltd. | 3.39% |
Name | Vivek Sharma | - |
Start Date | 11 Nov 2025 | - |
Name
Vivek Sharma
-
Start Date
11 Nov 2025
-
Description | The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 19 Nov 2024 | 01 Aug 2005 |
Description
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
19 Nov 2024
01 Aug 2005